Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2024-11-19

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2024-11-19

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

PREGABALIN

Canada Type II Ongoing · initiated 2024-11-19

Product quality - Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or …

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Evaric Pharmaceuticals Inc.

US Class II Terminated · initiated 2024-11-15

Presence of Foreign Object: A pharmacist discovered a metal fragment embedded in a lisinopril 10 mg tablet.